Accessibility Menu
Cochlear logo

Cochlear(OTC) CHEOF

Current Price$78.95
Market Cap$5.16BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)+275%
5 Year-51%
1 Year-58%
1 Month+3%
Cochlear last closing stock price
MetricPriceDate
Last closeUSD 78.952026-07-22
Cochlear stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.64%USD 81.922026-07-13
1 month+3.43%USD 76.332026-06-17
3 month+16.39%USD 67.832026-04-23
Year to date-52.59%USD 166.502025-12-31
1 year-58.3%USD 189.342025-07-21
3 year-46.32%USD 147.062023-07-20
5 year-51.43%USD 162.542021-07-23
Since inception+275.24%USD 21.042003-06-30

Cochlear Financials at a Glance

Market Cap

$5.16BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$4.67B

Net Income (TTM)

A$715.74M

EPS (TTM)

$3.39

P/E Ratio

23.20

Dividend

$2.93

Beta (Volatility)

0.09 (Low)

Price

$78.95

Volume

94

Open

$80.00

Previous Close

$78.95

Daily Range

$78.95 - $81.31

52-Week Range

$64.39 - $207.71

Estimated Earnings Date

Aug 13, 2026

CHEOF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cochlear

Cochlear Limited is an Australian company founded in 1981, specializing in advanced implantable hearing technology. The company develops and distributes a range of auditory solutions for both pediatric and adult populations globally.

Products and Services
  • Cochlear implant devices for hearing restoration
  • Bone conduction systems for individuals with conductive hearing loss
  • Sound processor upgrades and accessories for enhanced user experience
Growth Outlook
  • Projected revenue growth driven by increasing global demand for hearing solutions
  • Expansion into emerging markets to capture new customer segments
  • Investment in R&D to innovate and enhance product offerings
Financial Highlights
  • Recent quarterly revenue of AUD 1.18 billion, reflecting strong market performance
  • Trailing twelve months (TTM) net income of AUD 661 million, showcasing profitability
  • Dividend yield of 3.49%, indicating a commitment to returning value to shareholders
Cochlear Limited stands out in the medical devices industry with its innovative products that address hearing loss, a growing global health concern. The company's focus on research and development positions it well for future growth, particularly in emerging markets where access to hearing solutions is expanding. Recent financial performance highlights a robust revenue stream and profitability, making it an attractive option for investors interested in the healthcare sector. The commitment to shareholder returns through dividends further enhances its appeal.
AI Generated • Jul 9, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

5,500

CEO

Diggory William Howitt, MBA

Website

www.cochlear.com

Headquarters

Sydney, NSW 2109, AU

CHEOF Financials

Key Financial Metrics (TTM)

Gross Margin

73.03%

Operating Margin

19.98%

Net Income Margin

14.62%

Return on Equity

17.76%

Return on Capital

18.58%

Return on Assets

12.36%

Earnings Yield

4.31%

Dividend Yield

3.71%

Payout Ratio

81.47%

Stock Overview

Market Cap

$5.16BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

65.30M

Volume

94

Avg. Volume

1.65K

Financials (TTM)

Gross Profit

A$3.46B

Operating Income

A$966.61M

EBITDA

A$1.13B

Operating Cash Flow

A$606.05M

Capital Expenditure

-A$130.19M

Free Cash Flow

A$475.86M

Cash & ST Invst.

A$187.03M

Total Debt

A$427.63M

Cochlear Performance Analysis

Cochlear annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 1,190,266,458N/A
20232023-06-30AUD 1,315,608,22410.5%
20242024-06-30AUD 1,479,967,87812.5%
20252025-06-30AUD 1,525,689,0853.1%
Cochlear sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-302.1%
Q22024-12-303.1%
Q42025-06-301.2%
Q22025-12-31-0.9%
Cochlear annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD 3.19N/A
20232023-06-30AUD 3.07-3.7%
20242024-06-30AUD 3.5615.9%
20252025-06-30AUD 3.847.9%
Cochlear sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-13.4%
Q22024-12-3023.8%
Q42025-06-30-10.3%
Q22025-12-31-12.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$1.18B

+5.6%

Gross Profit

A$856.46M

+3.5%

Gross Margin

72.86%

N/A

Market Cap

$5.16BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$937.29K

N/A

Employees

5,500

N/A

Net Income

A$161.44M

-15.7%

EBITDA

A$272.29M

-9.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$187.03M

-61.5%

Total Debt

A$427.63M

+106.9%

Accounts Receivable

A$564.38M

+48.8%

Inventory

A$565.88M

+76.0%

Long Term Debt

A$385.45M

+130.9%

Short Term Debt

A$42.18M

+6.0%

Return on Assets

12.36%

N/A

Return on Invested Capital

21.12%

N/A

Free Cash Flow

A$108.76M

-4.9%

Operating Cash Flow

A$136.75M

-13.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ALBBYAlibaba Health Information Technology Limited
$8.47+0.00%
WILYYDemant A/S
$20.66+0.00%
WILLFDemant A/S
$41.51+0.00%
ERFSFEurofins Scientific SE
$73.75-0.36%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
NUNu Holdings
$14.09-0.01%

Questions About CHEOF

What is the current price of Cochlear?

Cochlear is trading at $78.95 per share.

What is the 52-week range for Cochlear?

Over the past 52 weeks, Cochlear has traded between $64.39 and $207.71.

How much debt does Cochlear have?

As of the most recent reporting period, Cochlear reported total debt of A$154.47M.

How much cash does Cochlear have on hand?

Cochlear reported A$180.68M in cash and cash equivalents in its most recent financial results.

What is Cochlear’s dividend yield?

Cochlear currently has a dividend yield of 3.71%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services